Enzyme News and Research

RSS

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009

Virtuoso cell engineering

University of Michigan researchers have discovered that a key protein in cells plays a critical role in not one, but two processes affecting the development of cancer.

6 Jan 2009

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals, Inc. has announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.

6 Jan 2009

Biologist finds plant polymerases IV and V are really variants of polymerase II

It's a little like finding out that Superman is actually Clark Kent. A team of biologists at Washington University in St. Louis has discovered that two vital cellular components, nuclear RNA Polymerases IV and V (Pol IV and V), found only in plants, are actually specialized forms of RNA Polymerase II, an essential enzyme of all eukaryotic organisms, including humans.

6 Jan 2009

Sildenafil may help protect heart from high blood pressure damage

Johns Hopkins and other researchers report what is believed to be the first direct evidence in lab animals that the erectile dysfunction drug sildenafil amplifies the effects of a heart-protective protein.

5 Jan 2009

Stem cells from human testes can change into other body tissues

Scientists at the Stanford University School of Medicine and at UC-San Francisco have succeeded in isolating stem cells from human testes.

5 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Antibodies take 'evolutionary leaps' to fight microbes

With cold and flu season in full swing, the fact that viruses and bacteria rapidly evolve is apparent with every sneeze, sniffle, and cough.

5 Jan 2009

Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2

Cylene Pharmaceuticals announced today that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma.

5 Jan 2009

Scientists genetically grab PTEN by the tail to curtail cancer

When researchers look inside human cancer cells for the whereabouts of an important tumor-suppressor, they often catch the protein playing hooky, lolling around in cellular broth instead of muscling its way out to the cells' membranes and foiling cancer growth.

1 Jan 2009

In lung cancer, silencing one crucial gene disrupts normal functioning of genome

While examining patterns of DNA modification in lung cancer, a team of international researchers has discovered what they say is a surprising new mechanism.

1 Jan 2009

Matrix fragments trigger fatal excitement

Shredded extracellular matrix (ECM) is toxic to neurons. Chen et al. reveal a new mechanism for how ECM demolition causes brain damage. The study will appear in the December 29, 2008 issue of The Journal of Cell Biology (www.jcb.org).

30 Dec 2008

Long-term gene therapy used to reverse heart damage in heart failure

Long-term gene therapy resulted in improved cardiac function and reversed deterioration of the heart in rats with heart failure, according to a recent study conducted by researchers at Thomas Jefferson University's Center for Translational Medicine.

30 Dec 2008

High-fat diet can disrupt our biological clock

Indulgence in a high-fat diet can not only lead to overweight because of excessive calorie intake, but also can affect the balance of circadian rhythms - everyone's 24-hour biological clock, Hebrew University of Jerusalem researchers have shown.

29 Dec 2008

FDA approves injectable drug degarelix for advanced prostate cancer

The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.

29 Dec 2008

Hexokinase-1 gene variation associated with widely used marker of blood glucose concentration

Scientists have found that genetic variation at the hexokinase-1 gene is linked to variation in the blood concentration of glycated hemoglobin, an index of long-term blood glucose concentration widely used in the follow-up of diabetes patients.

22 Dec 2008

Drinkers with the ADH1C gene at greater risk of colorectal cancer

Chronic drinking is a risk factor for colorectal cancer, possibly through the effects of acetaldehyde, which is created by the alcohol dehydrogenase (ADH) enzyme.

21 Dec 2008

Researchers identify gene linked to inherited form of fatal lung disease

Researchers at UT Southwestern Medical Center have determined that a mutation in a gene known for its role in defending the lungs against invading pathogens is responsible for some inherited cases of a lethal lung disease affecting older adults. The same mutation may also be associated with lung cancer, the researchers said.

21 Dec 2008

Stem cells may 'ignite' bowel cancer development

Cancer Research UK scientists have discovered for the first time that stem cells could be the root cause of bowel cancer, according to a study published in Nature.

18 Dec 2008

New understanding of RNA and evolution

With the aid of a straightforward experiment, researchers have provided some clues to one of biology's most complex questions: how ancient organic molecules came together to form the basis of life.

18 Dec 2008